You are here: Home » International » News » Markets
Business Standard

S&P 500, Dow dip as spiking Covid-19 infections eclipse vaccine hopes

The S&P 500 and the Dow were on track to post marginal losses for the week, while the tech-laden Nasdaq appeared set to settle a bit higher than last Friday's close

S&P 500 | Dow Jones | Coronavirus Vaccine

Reuters  |  NEW YORK 

Wall Street, US, stocks, US market
Traders work on the floor of the New York Stock Exchange (NYSE) in New York, US (Photo: Reuters)

By Stephen Culp

NEW YORK (Reuters) - The and the Dow edged lower on Friday as investors headed into the weekend grappling with disappointing fiscal stimulus news and uncertain efforts to combat a spiraling COVID-19 pandemic with vaccines.

Semiconductor stocks and other stay-at-home plays, which have thrived throughout the health crisis, helped keep the Nasdaq green.

Throughout the week, investors whipsawed between economically-sensitive cyclical stocks and pandemic-resistant market leaders.

The and the Dow were on track to post marginal losses for the week, while the tech-laden Nasdaq appeared set to settle a bit higher than last Friday's close.

"There's an ebb and flow to the market and the vaccine represents the hope," said Matthew Keator, managing partner at the Keator Group, a wealth management firm in Lenox, Massachusetts. "The time it will take to see it distributed and take effect reflects the reality of the situation. With the rising cases of the virus and the shutdowns at the state level that's something the market is paying close attention to."

U.S. Treasury Secretary Steven Mnuchin announced late Thursday that he would allow key pandemic-relief lending programs at the Federal Reserve to expire at the end of the year, saying the $455 billion allocated last spring under the CARES act should be returned to Congress to be reallocated as grants for small companies.

The decision to pull the plug on lending programs deemed essential by the central bank comes at a time of spiraling new infects and a fresh wave of layoffs, and was called "disappointing" by Chicago Federal Reserve president Charles Evans.

Record infection numbers have caused COVID hospitalizations to soar by 50% and have prompted a new round of school and businesses closures, curfews and social distancing restrictions, hobbling the economic recovery from the deepest recession since the Great Depression.

In the latest development in the race to develop a vaccine, Pfizer Inc said it would apply to the U.S. Food and Drug Administration for emergency use authorization of its COVID-19 vaccine, the first application of its kind in the battle against the disease.

The Industrial Average <.DJI> fell 132.83 points, or 0.45%, to 29,350.4, the <.SPX> lost 6.66 points, or 0.19%, to 3,575.21 and the Nasdaq Composite <.IXIC> added 20.16 points, or 0.17%, to 11,924.87.

Of the 11 major sectors in the S&P 500, industrials <.SPLRCI> were down the most, while utilities <.SPLRCU> were enjoying the largest percentage gains.

The Philadelphia SE Semiconductor index <.SOX> outperformed the broader market for the second straight session, rising 0.6%

Stay-at-home beneficiary Zoom Video Communications Inc was up 6.8%, providing the biggest lift to the Nasdaq, while reopening play Boeing Co was the heaviest drag on the blue-chip Dow.

Gilead Sciences Inc shed 0.8% as a World Health Organization panel advised against the use of the company's COVID-19 treatment remdesivir, citing lack of evidence the drug improves survival or reduces the need for ventilation.

Declining issues outnumbered advancing ones on the NYSE by a 1.08-to-1 ratio; on Nasdaq, a 1.06-to-1 ratio favored advancers.

The S&P 500 posted 16 new 52-week highs and no new lows; the Nasdaq Composite recorded 112 new highs and seven new lows.


(Reporting by Shivani Kumaresan and Medha Singh in Bengaluru and Stephen Culp in New York; Editing by Shounak Dasgupta and Tom Brown)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, November 21 2020. 01:21 IST